To include your compound in the COVID-19 Resource Center, submit it here.

Campath alemtuzumab: Phase IV data

An open-label, U.S. Phase IV trial in 474 renal transplant recipients at high or low immunologic risk showed that a single 30 mg dose of alemtuzumab met the primary endpoint of a significantly lower

Read the full 345 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE